OQS
ZYME icon

Occudo Quantitative Strategies’s Zymeworks ZYME Stock Holding History

Occudo Quantitative Strategies’s Portfolio ZYME Stock Details ZYME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-108,285
Closed -$709K – 1427
2022
Q1 		$709K Buy
+108,285
New +$965K 0.06% 509

Other funds holding ZYME

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $1.92B AUM 31.26% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Occudo Quantitative Strategies's ZYME Position: Q2 2022 in Review

Occudo Quantitative Strategies sold out of Zymeworks (ZYME) in Q2 2022, closing a stake of 108,285 shares — an estimated $709K sold.

Occudo Quantitative Strategies first reported a position in ZYME in Q1 2022 and held it in 1 quarter. The position peaked at $709K in Q1 2022. 113 funds tracked by Wall St. Rank hold ZYME as of Q2 2022.

  • Occudo Quantitative Strategies reported no remaining Zymeworks position as of Q2 2022 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 108,285 Zymeworks shares in Q2 2022, an estimated $709K.
  • Occudo Quantitative Strategies first reported a position in Zymeworks in Q1 2022 and held it in 1 quarter.
  • Occudo Quantitative Strategies's Zymeworks position peaked at $709K in Q1 2022.
  • 113 funds tracked by Wall St. Rank held Zymeworks as of Q2 2022.

Based on Occudo Quantitative Strategies's 13F filing for Q2 2022, filed 15 Aug 2022.